Is the repair of microbiotic imbalance the beginning of the story of cardiorenal protection?

7th International Congress of Cardionephrology KARNEF (2025) [pp. 85-91]

AUTHOR(S) / АУТОР(И): Pavel Skok 

Download Full Pdf   

DOI: 10.46793/KARNEF25.088S

ABSTRACT / САЖЕТАК:

The human microbiota is a community of bacteria, archaea, fungi, viruses and parasites that form an ecosystem consisting of approximately 1014 microorganisms. The diversity of this community is due to differences in the host’s genome and the influence of environmental factors, including hygiene, diet, lifestyle and the use of various drugs.  Research work in the recent past  has confirmed that the altered composition of the gut microbiota, dysbiosis, contributes to the development of various diseases, including cardiovascular, type 2 diabetes, chronic kidney disease, metabolic dysfunction-associated steatotic liver disease (MASLD), (formely non-alcoholic fatty liver disease, NASH), chronic inflammatory bowel disease and even some types of cancer.  In the article, the author present some modern knowledge about the diverse composition of the human intestinal microbiota, its alterations, dybiosis, and  the possibilities of changing the microbiota in the future.

KEYWORDS / КЉУЧНЕ РЕЧИ:

human gastrointestinal microbiota, dysbiosis, cardiovascular diseases, heart  failure, chronic kidney disease

REFERENCES / ЛИТЕРАТУРА:

  • Ursell LK, Haiser HJ, Van Treuren W, Garg N, Reddivari L, Vanamala J, Dorrestein PC, Turnbaugh PJ, Knight R. The intestinal metabolome: an intersection between microbiota and host. 2014;146(6):1470-6. doi: 10.1053/j.gastro.2014.03.001.                                                                            
  • Shreiner AB, Kao, JY, Young, V. B. The gut microbiome in health and in disease. Opin. Gastroenterol 2015;  31: 69–75.
  • Hillman ET, Lu H, Yao T, Nakatsu CH. Microbial ecology along the gastrointestinal tract. Microbes Environ 2017; 32:300–313.
  • Vangay P, Johnson AJ, Ward TL et al. US Immigration Westernizes the Human Gut Microbiome. Cell. 2018;175(4):962-972.e10.
  • Tang WHW, Kitai T, Hazen SL. Gut Microbiota in Cardiovascular Health and Disease. Circ Res. 2017;120(7):1183–96.
  • Adak A, Khan MR. An insight into gut microbiota and its functionalities. Cell Mol Life Sci. 2019;76(3):473-493. doi: 10.1007/s00018-018-2943-4.
  • Skok P. Gastrointestinal tract and associated heart and kidney diseases. V: Radenković S, (ur.), Šmelcerović A (ur.). Kardionefrologija = Cardionephrology. Niš: Punta, 2019. Str. 97-102.
  • Mahnic A, Breskvar M, Dzeroski S, Skok P, Pintar S, Rupnik M. Distinct Types of Gut Microbiota Dysbiosis in Hospitalized Gastroenterological Patients Are Disease Non-related and Characterized With the Predominance of Either Enterobacteriaceae or Enterococcus. Front Microbiol. 2020 Feb 11;11:120. doi: 10.3389/fmicb.2020.00120. eCollection 2020.
  • Skok P, Skok K. Gut microbiota and the pathophysiology of cardiovascular disease. Archives of Medical Science. 2021. https://www.archivesofmedicalscience.com/Gut-microbiota-and-the-pathophysiology-of-cardiovascular-disease,127177,0,2.html,DOI: 10.5114/aoms/127177.
  • Gomaa EZ. Human gut microbiota/microbiome in health and diseases: a review. Antonie Van Leeuwenhoek. 2020;113(12):2019-2040. doi: 10.1007/s10482-020-01474-7.
  • Tang WHW, Wang Z, Kennedy DJ et al. Gut microbiota-dependent trimethylamine N-oxide (TMAO) pathway contributes to both development of renal insufficiency and mortality risk in chronic kidney disease. Circ Res. 2014/11/05. 2015;116(3):448–55.
  • Zhu Q, Gao R, Zhang Y et al. Dysbiosis signatures of gut microbiota in coronary artery disease. Physiol Genomics. 2018;50(10):893–903.
  • Gansevoort RT, Correa-Rotter R, Hemmelgarn BR et al. Chronic kidney disease and cardiovascular risk: epidemiology, mechanisms, and prevention. Lancet. 2013; 382 (9889):339–52.
  • Shi K, Wang F, Jiang H et al. Gut Bacterial Translocation May Aggravate Microinflammation in Hemodialysis Patients. Dig Dis Sci. 2014;59(9):2109–17.
  • Rhee EP, Clish CB, Ghorbani A et al. A combined epidemiologic and metabolomic approach improves CKD prediction. J Am Soc Nephrol. 2013/05/16. 2013;24(8):1330–8.
  • Kazemian N, Mahmoudi M, Halperin F, Wu JC, Pakpour S. Gut microbiota and cardiovascular disease: opportunities and challenges. 2020;8(1):36.
  • Gomez-Arango LF, Barrett HL, McIntyre HD et al. Increased Systolic and Diastolic Blood Pressure is Associated with Altered Gut Microbiota Composition and Butyrate Production in Early Pregnancy. Hypertension. 2016;68(4):974–81.
  • Threapleton DE, Greenwood DC, Evans CEL et al. Dietary fibre intake and risk of cardiovascular disease: systematic review and meta-analysis. BMJ. 2013;347:f6879–f6879.
  • Aljuraiban GS, Griep LMO, Chan Q et al. Total, insoluble and soluble dietary fibre intake in relation to blood pressure: the INTERMAP Study. Br J Nutr. 2015/09/02. 2015;114(9):1480–6.
  • Ghosh TS, Rampelli S, Jeffery IB et al. Mediterranean diet intervention alters the gut microbiome in older people reducing frailty and improving health status: the NU-AGE 1-year dietary intervention across five European countries. Gut. 2020;69(7):1218 – 1228.
  • Leeming ER, Johnson AJ, Spector TD, Le Roy CI. Effect of Diet on the Gut Microbiota: Rethinking Intervention Duration. Nutrients. 2019;11(12):2862.
  • Cerasi M, Ammendola S, Battistoni A. Competition for zinc binding in the host-pathogen interaction. Front Cell Infect Microbiol. 2013;3:108.
  • Tebani A, Bekri S. Paving the Way to Precision Nutrition Through Metabolomics [Internet]. Vol. 6, Frontiers in Nutrition. 2019. p. 41.
  • Petriz BA, Castro AP, Almeida JA et al. Exercise induction of gut microbiota modifications in obese, non-obese and hypertensive rats. BMC Genomics. 2014;15(1):511.
  • Bear TLK, Dalziel JE, Coad J et al. The Role of the Gut Microbiota in Dietary Interventions for Depression and Anxiety. Adv Nutr. 2020;11(4):890–907.
  • Orimoloye OA, Kambhampati S, Hicks AJ et al. Higher cardiorespiratory fitness predicts long-term survival in patients with heart failure and preserved ejection fraction: The Henry Ford exercise Testing (FIT) project. Arch Med Sci. 2019;15(2):350–8.
  • Fiuza-Luces C, Santos-Lozano A, Joyner M et al. Exercise benefits in cardiovascular disease: beyond attenuation of traditional risk factors. Nat Rev Cardiol. 2018;15(12):731–43.